January 31, 2017
Ipsen buys gastrointestinal-focused-portfolio Italian company
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 31, 2017
India’s health bugdet may rise after minister warns of funding crunch
India’s health ministry is likely to see a substantial increase in funding, after it warned that its programs were short of cash and sought more than $1.2 billion in additional money
January 31, 2017
Teva launches two asthma products in 2017 to compete with GSK
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
European Commission OK’s Novartis’s tuberous sclerosis complex drug
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
January 31, 2017
TiGenix kicks off Sepcell trial to test new pneumonia treatment
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
January 30, 2017
Novo Nordisk invests £115 in new type 2 diabetes research with Oxford
Novo Nordisk and University of Oxford have expanded their partnership on researching type 2 diabetes, and will open a new research centre in Oxford.
January 30, 2017
Allergan’s to update label on its antibiotic Avycaz
Allergan has ensured permit to update the label for its Avycaz with new data from two third phase clinical trials, about treatining patients with certain complicated urinary tract infections (UTI).
January 30, 2017
Short: Shield’s secretary officially resigns
Shield Therapeutics has appointed Capita Registrars Limited as company secretary, after Richard Jones has officially resigned.